Peregrine Pharmaceuticals Announces Reverse Stock Split
July 07, 2017 10:25 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., July 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that a previously approved 1-for-7 reverse split of its outstanding...
Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock
June 06, 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017
June 05, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Negative PD-L1 Expression was Associated with a Significantly Longer Median Overall Survival Compared to Positive PD-L1 Expression in Patients Receiving Docetaxel Plus Bavituximab -- -- Presented...
Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
April 04, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- SUNRISE Data Analysis Demonstrates Statistically Significant Overall Survival (OS) Improvement in Patients Receiving Bavituximab plus Docetaxel and Subsequent Immunotherapy Compared to Placebo plus...
Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities
April 03, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Latest Findings from Ongoing Collaboration with Memorial Sloan Kettering (MSK) Support Potential Applications for Combining CAR T and Anti-PS in Treatment of Solid Tumors -- TUSTIN, Calif., April ...
Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting
March 23, 2017 07:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments
March 13, 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Revenue Guidance Increased to $60 - $65 Million for Full FY 2017 and Contracted Backlog of Future Business Currently at $70 Million ---- Multiple Preclinical Studies Demonstrating...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 09, 2017 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017
March 06, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
February 22, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced that the company...